Imatinib, a competitive inhibitor that binds to the ATP-binding site of BCR-ABL, is a first-generation BCR-ABL inhibitor that is highly effective against CML [16,17]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.